Drug intelligence / Profile preview

4SCAR19 + 4SCAR22

Development stage: Unknown
Lead developer: Shenzhen Geno-Immune Medical Institute
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

4SCAR19 + 4SCAR22 is a combination therapy consisting of two fourth-generation chimeric antigen receptor (CAR) T-cell products targeting CD19 and CD22 antigens, respectively. This dual-targeting approach is designed to prevent antigen escape, a common mechanism of relapse after single-target CAR T-cell therapy. Fourth-generation CAR T cells typically include additional safety features such as inducible caspase 9 (iCasp9) for better control of potential adverse effects.

Targets

CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on 4SCAR19 + 4SCAR22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4SCAR19 + 4SCAR22.

Explore the full profile